



COVID-19 Infection and Hematological Malignancies

Guest Editor:

Prof. Dr. Mingyi Chen

Department of Pathology,
University of Texas Southwestern
Medical Center, Dallas, TX 75390,
USA

Deadline for manuscript
submissions:

closed (15 March 2023)

Message from the Guest Editor

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) in March 2020. In the past three years, COVID-19 has spread worldwide, causing several million deaths. Patients with hematological malignancies (HMs) are at high risk of developing severe and life-threatening infections, as they often have immune deficiency and are recipients of immunosuppressive treatments. Therefore, patients with hematological malignancies are at high risk of mortality due to COVID-19. A better understanding of the risk factors for adverse outcomes may facilitate improved clinical management of these patients.

This Special Issue is dedicated to the diagnosis and treatment of hematological malignancies during COVID-19 infection. We thank all the authors who will contribute articles regarding these interesting and timely topics. We hope this Special Issue is educational for caregivers in their daily practice toward enabling high-quality patient care.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)